| Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis |
The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2026 | | Cost | | Unrealized Gains (Losses) | | Accrued Interest | | Estimated Fair
Value | | Cash & Cash
Equivalents | | Investment
Securities | | | | | | | | | | | | | | Cash and cash equivalents, excluding money market accounts | $ | 50,764 | | $ | — | | $ | — | | $ | 50,764 | | $ | 50,764 | | $ | — | | | | | | | | | | | | | | Level 1: | | | | | | | | | | | | | Money market accounts | 21,146 | | — | | — | | 21,146 | | 21,146 | | — | | Government & agency securities | 42,488 | | 71 | | 71 | | 42,630 | | — | | 42,630 | | | | | | | | | | | | | | 63,634 | | 71 | | 71 | | 63,776 | | 21,146 | | 42,630 | | | | | | | | | | | | | | Level 2: | | | | | | | | | | | | Corporate bonds | 54,827 | | (61) | | 515 | | 55,281 | | — | | 55,281 | | | | | | | | | | | | | | Total | $ | 169,225 | | $ | 10 | | $ | 586 | | $ | 169,821 | | $ | 71,910 | | $ | 97,911 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | December 31, 2025 | | Cost | | Unrealized Gains | | Accrued Interest | | Estimated Fair
Value | | Cash & Cash
Equivalents | | Investment
Securities | | | | | | | | | | | | | | Cash and cash equivalents, excluding money market accounts | $ | 50,187 | | $ | — | | $ | — | | $ | 50,187 | | $ | 50,187 | | $ | — | | | | | | | | | | | | | | Level 1: | | | | | | | | | | | | | Money market accounts | 39,116 | | — | | — | | 39,116 | | 39,116 | | — | | Government & agency securities | 23,247 | | 111 | | 80 | | 23,438 | | — | | 23,438 | | 62,363 | | 111 | | 80 | | 62,554 | | 39,116 | | 23,438 | | | | | | | | | | | | | | Level 2: | | | | | | | | | | | | | Corporate bonds | 53,801 | | 198 | | 533 | | 54,532 | | — | | 54,532 | | | | | | | | | | | | | | Total | $ | 166,351 | | $ | 309 | | $ | 613 | | $ | 167,273 | | $ | 89,303 | | $ | 77,970 | | | | | | | | | | | | |
|
| Schedule of Investment Losses |
The gains related to the Company’s LifeMD investment for the three and six months ended June 30, 2026 and 2025 are summarized in the table below (in thousands): | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | | | 2026 | | 2025 | | | | | | | | | | Net gains recognized during the period on equity securities | $ | — | | | $ | 2,622 | | | | | Less: Net gains recognized on equity securities sold | — | | | 2,622 | | | | | Unrealized gains recognized during the reporting period on equity securities still held at the reporting date | $ | — | | | $ | — | | | |
| | | | | | | | | | | | | Six months ended June 30, | | 2026 | | 2025 | | | | | | Net gains recognized during the period on equity securities | $ | — | | | $ | 3,222 | | | Less: Net gains recognized on equity securities sold | — | | | 3,222 | | | Unrealized gains recognized during the reporting period on equity securities still held at the reporting date | $ | — | | | $ | — | |
|